Taho Pharmaceuticals Ltd. (TPEX:6467)

Taho Pharmaceuticals Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	99.77	339.98	245.87	151.71	74.3	39.22
Short-Term Investments	200	50	250	78.07	32	42
Cash & Short-Term Investments	299.77	389.98	495.87	229.77	106.3	81.22
Cash Growth	-25.34%	-21.36%	115.81%	116.16%	30.87%	-36.85%
Accounts Receivable	0.9	0.16	-	-	-	1.39
Other Receivables	1.18	0.65	0.87	0.29	0.03	0.01
Receivables	2.08	0.8	0.87	0.29	0.03	1.39
Prepaid Expenses	1.81	2.85	2.18	3.24	4.96	0.64
Other Current Assets	-	-	-	-	-	0.15
Total Current Assets	303.66	393.62	498.92	233.31	111.29	83.41
Property, Plant & Equipment	22.5	22.45	24.86	23.55	4.33	12.35
Long-Term Investments	7.96	7.86	8.01	-	-	-
Other Intangible Assets	0.63	0.74	-	-	-	-
Other Long-Term Assets	29.69	30.92	28.91	26.34	22.93	13.47
Total Assets	364.43	455.6	560.7	283.2	138.54	109.23

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accrued Expenses	9.15	17.73	24.74	21.53	10.5	3.63
Current Portion of Leases	5.66	5.55	5.34	4.97	-	4.92
Current Unearned Revenue	-	-	0.71	-	0.19	1.85
Other Current Liabilities	1.79	2.76	2.28	33.2	35.8	2.6
Total Current Liabilities	16.59	26.04	33.06	59.7	46.49	12.99
Long-Term Leases	2.91	5.77	11.31	16.65	-	-
Other Long-Term Liabilities	0.08	0.09	0.12	0.15	-	32
Total Liabilities	19.58	31.9	44.5	76.5	46.49	44.99

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	523.71	523.56	512.16	423.07	372.97	346.56
Additional Paid-In Capital	28.82	114.69	388.42	256.19	70.96	2.62
Retained Earnings	-208	-214.4	-384.38	-472.57	-351.89	-285.59
Comprehensive Income & Other	0.33	-0.15	-	-	-	0.64
Shareholders' Equity	344.86	423.7	516.2	206.69	92.05	64.23
Total Liabilities & Equity	364.43	455.6	560.7	283.2	138.54	109.23

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	8.57	11.31	16.65	21.62	-	4.92
Net Cash (Debt)	291.2	378.66	479.22	208.15	106.3	76.31
Net Cash Growth	-24.85%	-20.98%	130.22%	95.82%	39.30%	-40.26%
Net Cash Per Share	5.60	7.36	10.56	5.37	2.96	2.20
Filing Date Shares Outstanding	52.41	52.36	51.22	51.22	37.3	34.66
Total Common Shares Outstanding	52.41	52.36	51.22	51.22	37.3	34.66
Working Capital	287.06	367.58	465.86	173.61	64.79	70.41
Book Value Per Share	6.58	8.09	10.08	4.04	2.47	1.85
Tangible Book Value	344.23	422.96	516.2	206.69	92.05	64.23
Tangible Book Value Per Share	6.57	8.08	10.08	4.04	2.47	1.85
Machinery	65.99	62.3	59.45	52.84	54.42	53.77
Leasehold Improvements	18.06	17.25	14.03	13.81	13.75	13.71

Data Source: S&P Global Market Intelligence Last updated: Aug 14, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 18, 2026

Data Sources Report a data error